Reform of pharma legislation: the debate on regulatory data protection
by Giuliana Miglierini As the definition of the final contents of many new pieces of the overall revision…
What happens after IP loss of protection
by Giuliana Miglierini What does it happen under a competitiveness perspective once intellectual property (IP) protection for medicinal…
The main contributions to the consultation on the revision of the pharmaceutical legislation
by Giuliana Miglierini The European Commission has published the summary of the outcomes of the public consultation on…